Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients ...Middle East

LUND, Sweden, Aug. 2, 2021 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that its first-in-class treatment Idefirix®▼ (imlifidase) is, as of August 1, reimbursable and available for...

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma announces reimbursement in the Netherlands of Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients )

Also on site :

• ‘She lit up the classroom’: First British victims of Air India plane crash named after 241 killed
• Increased ICE detentions and deportations create climate of fear and stress
• Numbrix 9 - June 13